nach oben

Journal of Gastroenterology

Erschienen in:

28.11.2019 | Editorial

Is metabolic syndrome responsible for the progression from NAFLD to NASH in non-obese patients?

verfasst von: Takumi Kawaguchi, Takuji Torimura

Erschienen in: Journal of Gastroenterology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Excerpt

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease and is a risk factor for significant hepatic fibrosis [1, 2]. Since there are multiple pathogeneses for NAFLD, various subgroups are seen in patients with NAFLD [3]. “Non-obese NAFLD with metabolic syndrome (MS)” is one subgroup, and a noteworthy fact is that this subgroup is growing increasingly prevalent [4, 5]. However, limited information is available regarding the prevalence and risk factors for non-alcoholic steatohepatitis (NASH) and significant fibrosis in non-obese patients with NAFLD. …

Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson PA, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018;155:1828–37 (e2).CrossRef

Brar G, Tsukamoto H. Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science. J Gastroenterol. 2019;54:218–25.CrossRef

Eslam M, Sanyal AJ, George J. Toward more accurate nomenclature for fatty liver diseases. Gastroenterology. 2019;157:590–3.CrossRef

Nishioji K, Sumida Y, Kamaguchi M, Mochizuki N, Kobayashi M, Nishimura T, et al. Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011–2012. J Gastroenterol. 2015;50:95–108.CrossRef

Stefan N, Schick F, Haring HU. Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans. Cell Metab. 2017;26:292–300.CrossRef

Kim D, Kim W, Joo SK, Han J, Kim JH, Harrison SA, et al. Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis. J Gastroenterol. 2019. https://doi.org/10.1007/s00535-019-01628-z.CrossRefPubMed

Wei JL, Leung JC, Loong TC, Wong GL, Yeung DK, Chan RS, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol. 2015;110:1306–14 (quiz 15).CrossRef

Fracanzani AL, Petta S, Lombardi R, Pisano G, Russello M, Consonni D, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity. Clin Gastroenterol Hepatol. 2017;15:1604–11 (e1).CrossRef

Argo CK, Henry ZH. Editorial: "Lean" NAFLD: metabolic obesity with normal BMI.. is it in the genes? Am J Gastroenterol. 2017;112:111–3.CrossRef

10.

Tobari M, Hashimoto E, Taniai M, Ikarashi Y, Kodama K, Kogiso T, et al. Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: not uncommon and not always benign. J Gastroenterol Hepatol. 2019;34:1404–10.CrossRef

11.

Li C, Guo P, Okekunle AP, Ji X, Huang M, Qi J, et al. Lean non-alcoholic fatty liver disease patients had comparable total caloric, carbohydrate, protein, fat, iron, sleep duration and overtime work as obese non-alcoholic fatty liver disease patients. J Gastroenterol Hepatol. 2019;34:256–62.CrossRef

12.

Wong VW, Wong GL, Chan RS, Shu SS, Cheung BH, Li LS, et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol. 2018;69:1349–56.CrossRef

13.

Kwak JH, Jun DW, Lee SM, Cho YK, Lee KN, Lee HL, et al. Lifestyle predictors of obese and non-obese patients with nonalcoholic fatty liver disease: a cross-sectional study. Clin Nutr. 2018;37:1550–7.CrossRef

14.

Srikanthan P, Hevener AL, Karlamangla AS. Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: findings from the National Health and Nutrition Examination Survey III. PLoS ONE. 2010;5:e10805.CrossRef

15.

Vila IK, Park MK, Setijono SR, Yao Y, Kim H, Badin PM, et al. A muscle-specific UBE2O/AMPKalpha2 axis promotes insulin resistance and metabolic syndrome in obesity. JCI Insight. 2019. https://doi.org/10.1172/jci.insight.128269.CrossRefPubMedPubMedCentral

Titel: Is metabolic syndrome responsible for the progression from NAFLD to NASH in non-obese patients?
verfasst von: Takumi Kawaguchi
Takuji Torimura
Publikationsdatum: 28.11.2019
Verlag: Springer Singapore
Erschienen in: Journal of Gastroenterology / Ausgabe 3/2020
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI: https://doi.org/10.1007/s00535-019-01650-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Is metabolic syndrome responsible for the progression from NAFLD to NASH in non-obese patients?

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Patients with dyspepsia have impaired mucosal integrity both in the duodenum and jejunum: in vivo assessment of small bowel mucosal integrity using baseline impedance

Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial

Clinical relevance of esophageal subepithelial activity in eosinophilic esophagitis

Abdominal obesity increases risk for esophageal cancer: a nationwide population-based cohort study of South Korea

Correction to: Risk of gastric cancer in the second decade of follow-up after Helicobacter pylori eradication

Emerging therapies for PBC

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin